Bisphosphonates in patients with glucocorticoids: Time for implementation

Journal of Rheumatology

Volumn 36, Issue 8, 2009, Pages 1570-1572

  Lems, Willem F ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITRIOL; CALCIUM; GLUCOCORTICOID; OSTEOCLAST DIFFERENTIATION FACTOR; PARATHYROID HORMONE[1-34]; PREDNISONE; RISEDRONIC ACID; VITAMIN D; ZOLEDRONIC ACID;

BONE DENSITY; CALCIUM ABSORPTION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DOSAGE SCHEDULE COMPARISON; DRUG WITHDRAWAL; EDITORIAL; FRACTURE; HUMAN; HYPERTENSION; INFECTION; LIFESTYLE MODIFICATION; LUMBAR SPINE; MUSCLE WEAKNESS; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT; VERTEBRA FRACTURE;

DIPHOSPHONATES; DRUG THERAPY, COMBINATION; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS; RHEUMATIC DISEASES;

EID: 68849107051     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090535     Document Type: Editorial

References (21)

1. Lems WF. Bisphosphonates and glucocorticoids: effects on bone quality. Arthritis Rheum 2007;56:3518-22.
2. van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue Int 2006;79:129-37.
3. Curtis JR, Saag KG. Prevention and treatment of glucocorticoid-induced osteoporosis. Curr Osteoporos Rep 2007;5:14-21.
4. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology 2000;39:1383-9.
5. Recommendations for the prevention and treatment of glucocorticoid- induced osteoporosis: 2001 update. American College of Rheumatology Adhoc Committee on Glucocorticoid-induced Osteoporosis. Arthritis Rheum 2001;44:1496-503.
6. Geusens PP, De Nijs RN, Lems WF, et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004;63:324-5.
7. Solomon DH, Katz JN, Cabral D, et al. Osteoporosis management in patients with rheumatoid arthritis: evidence for improvement. Arthritis Rheum 2006;55:873-7.
8. Duyvendak M, Naunton M, Atthobari J, et al. Corticosteroid-induced osteoporosis prevention: Longitudinal practice patterns in the Netherlands 2001-2005. Osteoporos Int 2007;18:1429-33.
9. Guzman-Clark JR, Fang MA, Sehl ME, et al. Barriers in the management of glucocorticoid-induced osteoporosis. Arthritis Rheum 2007;57:140-6.
10. Dawson Hughes B, Tosteson ANA, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis guidelines in the USA. Osteoporos Int 2008;19:449-58.
11. Newman ED, Matzko CK, Olenginski TP, et al. Glucocorticoid-Induced Osteoporosis Program: a novel, comprehensive and highly successful program with improved outcomes at 1 year. Osteoporos Int 2006;17:1428-34.
12. Cramer JA, Lynch NO, Gaudin AF, Walker M, Cowell W. The effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and France. Clin Ther 2006;28:1686-94.
13. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2008;81:1013-22.
14. Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a randomized, placebo-controlled trial: J Rheumatol 2009;36:1705-14.
15. European Medicines Agency. Guideline on the evaluation of new medical products in the treatment of primary osteoporosis. London, 14 December 2005.
16. Saag K, Emkey R, Schnitzer TJ, al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
17. Lems WF, Lodder MC, Lips P, et al. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone. Osteoporos Int 2006;17:716-23.
18. De Nijs RN, Jacobs JW, Lems WF, et al. Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis. N Engl J Med 2006;355:675-84.
19. Wallach S, Cohen S, Reid DM, et al. Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy. Calcif Tissue Int 2000;67:277-85.
20. Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of GIOP. Lancet 2009;373:1253-63.
21. Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007;357:2028-39.